The phase 2 SWOG S1505 study, evaluating the efficacy and safety of 2 perioperative chemotherapy regimens, failed to reach its primary endpoint as overall survival (OS) at 2 years did not exceed the prespecified threshold.
Dissection followed by adjuvant chemotherapy remains the standard-of-care for resectable pancreatic cancer. However, outcomes remain suboptimal, due to the inability of many patients to receive adjuvant chemotherapy as well as early progression in the perioperative period. Perioperative chemotherapy using aggressive multi-agent chemotherapy regimens for early control of systemic disease could overcome these problems.
Key eligibility criteria for SWOG S1505, designed to evaluate efficacy and safety of both modified FOLFIRINOX and gemcitabine plus nab-paclitaxel, included a confirmed tissue diagnosis of pancreatic adenocarcinoma . No prior cancer therapy of any kind was allowed. Resectability was strictly defined, using a contras...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Cardiotoxicity: consider switching to S-1 Next Article
Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.